Thromb Haemost 1977; 37(01): 162-169
DOI: 10.1055/s-0038-1649214
Original Article
Schattauer GmbH

Intermittent Plasminogen-Streptokinase Treatment of Deep Vein Thrombosis

M. F Scully
1  Thrombosis Research Unit, King’s College Hospital Medical School, Denmark Hill, London SE5 8RX, England
,
D. A Lane
1  Thrombosis Research Unit, King’s College Hospital Medical School, Denmark Hill, London SE5 8RX, England
,
S Sagar
1  Thrombosis Research Unit, King’s College Hospital Medical School, Denmark Hill, London SE5 8RX, England
,
D. P Thomas
1  Thrombosis Research Unit, King’s College Hospital Medical School, Denmark Hill, London SE5 8RX, England
,
V. V Kakkar
1  Thrombosis Research Unit, King’s College Hospital Medical School, Denmark Hill, London SE5 8RX, England
› Author Affiliations
Further Information

Publication History

Received 04 August 1976

Accepted 20 October 1976

Publication Date:
03 July 2018 (online)

Summary

The fibrinolytic response of 12 patients receiving single daily infusions of 600,000 units of streptokinase (SK) and 90 mg of plasminogen for the treatment of DVT has been studied. The mean plasminogen concentration was maintained throughout the treatment period (4–6 days) at between 20–40 % the initial value, while mean circulating plasmin concentration rose to only about twice initial plasma levels. The degradation of fibrinogen as indicated by a fall in clottable fibrinogen and rise in serum FDP varied appreciably from patient to patient. In 9 patients fibrinogen did not fall below 1 mg/ml and serum FDP rose to greater than 1 mg/ml. Limited fibrinogenolysis occurred in 2 patients, while in another patient who bled there was immediate and extensive depletion to below 0.5 mg/ml. The beneficial clinical results obtained with this regimen (Kakkar et al. 1975), which produces only limited systemic plasminaemia, suggest that thrombolysis may be facilitated by higher levels of plasminogen than those maintained during conventional SK treatment.